重组人血管内皮抑制素联合化疗治疗晚期结直肠癌的疗效分析

Analysis on Recombinant Human Endostatin Combined With Chemotherapy in Treatment of Later Period Colorectal Cancer

目的探究晚期结直肠癌患者采用重组人血管内皮抑制素（恩度）联合化疗的治疗方法和效果。方法选取2014年8月-2015年8月收治33例晚期结直肠癌患者进行治疗,随机分组,实验组19例选择恩度联合化疗的治疗干预,对照组14例患者仅接受化疗治疗,比较两组患者的治疗效果。结果实验组治疗的总缓解率为31.6%,对照组治疗的总缓解率为14.3%。实验组患者的总缓解率高于对照组,差异有统计学意义（P〈0.05）。结论晚期结直肠癌患者采用恩度联合化疗的治疗,疗效显著,不良反应率低,提高身体舒适度。

Objective Make an investigation on recombinant human endostatin（endostar）combined with chemotherapy treatment method and its effect in treatment of colorectal cancer later period. Methods Chose 33 patients of colorectal cancer later period who were treated in hospital from August 2014 to August 2015 and separated them into two groups at random,19 patients in study group were given endostar combined with chemotherapy treatment,while another 14 patients in control group were given chemotherapy only,and then compared treatment effects between two groups. Results Patients＇ symptoms-relieved rate in study group was 31.6%,while patients＇ symptoms-relieved rate in control group was 14.3%. Thus,patients＇ symptomsrelieved rate was much higher in study group compared to that in control group,there was a differential between two groups and such a differential had statistic value（P〈0.05）. Conclusion Endostar combined with chemotherapy is effective in treatment of colorectal cancer later period with low side-effect incidence and it is conducive to promoting patients＇ physical comfort.